Drug Database
Back to search

Belgium· BE-AMP-SAM599306-00

Vydura 75 mg

A rimegepant product containing rimegepant sulfate, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 16 of our 19 countries.

ATC N02CD06

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedVydura 75 mgATCN02CD06REGISTER NO.BE-AMP-SAM599306-00PACKS LISTED3CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rimegepant sulfateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rimegepant is registered in 16 of 19 countries.

Countries holding a registration under ATC N02CD06 (rimegepant), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 11 of them publish a price we can compare per daily dose
Search rimegepant products by name

Rimegepant · ATC N02CD06

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rimegepant costs, country by country.

Normalised to the WHO defined daily dose (37.5 mg), the median price runs from $14.84 in Switzerland to $64.33 in United States — a ×4.3 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Rimegepant · price per daily dose (37.5 mg)

USD · FX 28 Sept 2026

  • US United States$64.33 (acquisition cost)
  • IT Italy$18.89
  • ES Spain$16.29
  • CH Switzerland$14.84
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Rimegepant Sulfate
Manufacturer
Pfizer Europe MA
Country
Belgium (BE)
ATC code
N02CD06
ATC class
Rimegepant
Defined daily dose
37.5 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 3

  • be_apb
    4567855
  • be_apb
    4567848
  • be_apb
    4567863

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

90 interactions on record for rimegepant.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rimegepant against other medicinesHow interaction checks work

Rimegepant · interactions on record

90 records

  • 9 severe
  • 81 moderate

Most severe, free to view

  • DexamethasoneH02AB02severe
  • DabrafenibL01EC02severe
  • LorlatinibL01ED05severe
  • DabrafenibL01XE23severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rimegepant in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rimegepant products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Vydura
  • Liechtenstein · Vydura
  • Norway · Vydura

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/aca84c51-74ae-4530-82be-e100cd18130c
GET /v1/drugs/aca84c51-74ae-4530-82be-e100cd18130c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oral lyophilisate",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Vydura 75 mg",
  "name_fr": "Vydura 75 mg",
  "name_nl": "Vydura 75 mg",
  "amp_code": "SAM599306-00",
  "strengths": [
    "75.0000",
    "75.0000",
    "75.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Rimegepant Sulfate",
    "Rimegepant",
    "Mannitol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Rimegepant",
  "authorisation_numbers": [
    "EU/1/22/1645/002",
    "EU/1/22/1645/001",
    "EU/1/22/1645/003"
  ]
}
API referenceMCP serverPlans

See everything about rimegepant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console